TIGIT and breast cancer: Moreover, the finding that their expression levels were associated with PD-1+ and PD-L1+ cells supports the development of combination strategies to concomitantly target the PD1-PD-L1 and TIGIT-PVR axes in this highly aggressive breast cancer subtype, particularly in non-molecular apocrine TNBC.